Takeda’s Alogliptin Falls Prey To FDA Slowdown
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay is no bellwether for oral anti-diabetic drugs, the firm says.
You may also be interested in...
FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
FDA may be heeding stakeholder calls to set new action dates once an original user fee deadline is missed.
FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
FDA may be heeding stakeholder calls to set new action dates once an original user fee deadline is missed.
Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008
Japanese firm incurs “income contraction” for the first time in 17 years.